Latest Updates

On Monday, April 27, a bipartisan letter was sent to U.S. House and Senate leadership urging for the inclusion of pharmacy DIR reform in the next COVID-19 relief package. The bipartisan House letter, led by Reps. Buddy Carter (R-GA), Peter Welch (D-VT), Raja Krishnamoorthi (D-IL), John Rose (R-TN), Vicente Gonzales (D-TX), and Doug Collins (R-GA), garnered 115 signers in the House of Representatives, the most number of signatures ever on a DIR fee focused Congressional letter.

As scientists are working around the clock to develop a COVID-19 vaccine, GNP and ABC are collaborating with ADPC members to call on states to remove barriers that prevent pharmacists from administering vaccines. Learn more here and read a letter the coalition recently sent to HHS Assistant Secretary for Health, Admiral Brett Giroir, M.D.

On April 8th the U.S. Department of Health and Human Services (HHS) made the historic decision to allow pharmacists to order and administer FDA approved COVID-19 tests. Empowering pharmacists to test for COVID-19 is a policy GNP and ABC have advocated for, and we are pleased to see this recent HHS guidance. However, in California pharmacists are still unable to administer COVID-19 tests due to existing state restrictions.

On April 8th the U.S. Department of Health and Human Services (HHS) made the historic decision to allow pharmacists to order and administer FDA approved COVID-19 tests. Empowering pharmacists to test for COVID-19 is a policy GNP and ABC have advocated for, and we are pleased to see this recent HHS guidance. However, in New York pharmacists are still unable to administer COVID-19 tests due to existing state restrictions.

Please contact your representative today to encourage them to sign onto a bipartisan letter to Congressional Leadership calling for the inclusion of pharmacy DIR fee relief in the next COVID-19 legislative package. Visit NCPA’s legislative action center at this link to contact your representative today!